Relmada Therapeutics (RLMD) Q2 FY26 earnings call

Relmada Therapeutics is in a critical execution phase, focusing on advancing its lead assets, NDV-01 and Cepranolone, towards registrational development. While manufacturing timelines for NDV-01 have shifted, the company maintains a strong cash position to fund operations through 2029 and is confident in its clear plan to file both INDs by year-end 2026. The company highlights the potential of NDV-01 as a best-in-class therapy for NMIBC, leveraging a well-established therapeutic foundation and favorable Phase 2 data.